• Popular
    • Medicine
    • Radiology
    • Cardiology
    • Surgery
    • Nanomedicine
    • Military Medicine
    • Rehab
  • Categories
    • Exclusive
    • A-D
      • Anesthesiology
      • Art
      • Cardiac Surgery
      • Cardiology
      • Critical Care
      • Dentistry
      • Dermatology
      • Diagnostics
    • E-I
      • Emergency Medicine
      • ENT
      • Genetics
      • Geriatrics
      • GI
      • Informatics
    • M-N
      • Medicine
      • Military Medicine
      • Nanomedicine
      • Net News
      • Neurology
      • Neurosurgery
      • Nuclear Medicine
    • O-P
      • Ob/Gyn
      • Oncology
      • Ophthalmology
      • Orthopedic Surgery
      • Pathology
      • Pediatrics
      • Plastic Surgery
      • Psychiatry
      • Public Health
    • R-V
      • Radiation Oncology
      • Radiology
      • Rehab
      • Reproductive Medicine
      • Space Medicine
      • Sports Medicine
      • Surgery
      • Thoracic Surgery
      • Urology
      • Vascular Surgery
  • SUBSCRIBE
  • Submit PR
  • About
  • Follow
    • Facebook
    • Twitter
    • Linkedin
    • Youtube
    • Instagram
    • RSS
  • Submit PR
  • Log in
Medgadget
Medgadget
  • Popular
    • Medicine
      Flexible Sensors Detect Heavy Metals in Sweat

      Flexible Sensors Detect Heavy Metals in Sweat

      Nanopore Sensor to Study Protein Aggregation in Neurodegeneration

      Nanopore Sensor to Study Protein Aggregation in Neurodegeneration

      Biobots Use Optogenetic Muscle Actuators for Movement

      Biobots Use Optogenetic Muscle Actuators for Movement

      Exciting Medtech at the Healthcareᐩ Expo Taiwan

      Exciting Medtech at the Healthcareᐩ Expo Taiwan

    • Radiology
      Ultrasound Tornado Rapidly Disrupts Blood Clots

      Ultrasound Tornado Rapidly Disrupts Blood Clots

      Exciting Medtech at the Healthcareᐩ Expo Taiwan

      Exciting Medtech at the Healthcareᐩ Expo Taiwan

      Fluorescence Imaging System Illuminates Tumor Depth

      Fluorescence Imaging System Illuminates Tumor Depth

      Soft Robot Grows Like a Plant to Travel Through Tight Spaces

      Soft Robot Grows Like a Plant to Travel Through Tight Spaces

    • Cardiology
      Belt Monitors Heart Failure Patients

      Belt Monitors Heart Failure Patients

      Camera Measures Blood Pressure with Quick Look

      Camera Measures Blood Pressure with Quick Look

      Monitoring Congestive Heart Failure Through Speech: Interview with Tamir Tal, CEO of Cordio Medical

      Monitoring Congestive Heart Failure Through Speech: Interview with Tamir Tal, CEO of Cordio Medical

      Device Measures Hemoglobin More Accurately in Dark Skin

      Device Measures Hemoglobin More Accurately in Dark Skin

    • Surgery
      Microneedle Bandage for Hemostatic Control

      Microneedle Bandage for Hemostatic Control

      Biobots Use Optogenetic Muscle Actuators for Movement

      Biobots Use Optogenetic Muscle Actuators for Movement

      Implantable Device Adheres to Muscle, Treats Atrophy

      Implantable Device Adheres to Muscle, Treats Atrophy

      Device Measures Hemoglobin More Accurately in Dark Skin

      Device Measures Hemoglobin More Accurately in Dark Skin

    • Nanomedicine
      Extra Hot Nanoparticles for Cancer Therapy

      Extra Hot Nanoparticles for Cancer Therapy

      Making Tumors Tastier for the Immune System

      Making Tumors Tastier for the Immune System

      Improved Membrane Coating for Anti-Cancer Nanoparticles

      Improved Membrane Coating for Anti-Cancer Nanoparticles

      Magnetic Bacteria Target Tumors

      Magnetic Bacteria Target Tumors

    • Military Medicine
      Device Measures Hemoglobin More Accurately in Dark Skin

      Device Measures Hemoglobin More Accurately in Dark Skin

      Fingertip Sensor Measures Lithium Levels in Sweat

      Fingertip Sensor Measures Lithium Levels in Sweat

      Fabric Makes Electricity from Movement to Power Wearables

      Fabric Makes Electricity from Movement to Power Wearables

      Wearable Uses Microneedles to Track Metabolism

      Wearable Uses Microneedles to Track Metabolism

    • Rehab
      Smart Walking Stick for Visually Impaired People

      Smart Walking Stick for Visually Impaired People

      Implantable Device Adheres to Muscle, Treats Atrophy

      Implantable Device Adheres to Muscle, Treats Atrophy

      Non-Invasive Spinal Modulation for Cerebral Palsy

      Non-Invasive Spinal Modulation for Cerebral Palsy

      Implanted Magnets for Prosthetic Control

      Implanted Magnets for Prosthetic Control

  • Categories
    • Exclusive
    • A-D
      • Anesthesiology
      • Art
      • Cardiac Surgery
      • Cardiology
      • Critical Care
      • Dentistry
      • Dermatology
      • Diagnostics
    • E-I
      • Emergency Medicine
      • ENT
      • Genetics
      • Geriatrics
      • GI
      • Informatics
    • M-N
      • Medicine
      • Military Medicine
      • Nanomedicine
      • Net News
      • Neurology
      • Neurosurgery
      • Nuclear Medicine
    • O-P
      • Ob/Gyn
      • Oncology
      • Ophthalmology
      • Orthopedic Surgery
      • Pathology
      • Pediatrics
      • Plastic Surgery
      • Psychiatry
      • Public Health
    • R-V
      • Radiation Oncology
      • Radiology
      • Rehab
      • Reproductive Medicine
      • Space Medicine
      • Sports Medicine
      • Surgery
      • Thoracic Surgery
      • Urology
      • Vascular Surgery
  • SUBSCRIBE
  • Submit PR
  • About
  • Log in
  • Submit PR
  • Follow
    • Facebook
    • Twitter
    • Linkedin
    • Youtube
    • Instagram
    • RSS

U.S. Non-oncology Biopharmaceuticals Market Size & Trends 2021 – expected to reach US$ 253.0 Bn With CAGR of 10.2% by 2026 | Sanofi S.A., Pfizer, Inc., Johnson & Johnson, Novartis International AG, Amgen

October 8th, 2021 Coherent Market Insights Releases

The U.S. Non-oncology Biopharmaceuticals Market, by Product Type (Biosimilars and Biologics), by Drug Class (Human Recombinant Insulin, Monoclonal Antibody, Botulinum Toxin, Human Growth Hormone, Interferon, Enzyme Replacement Therapy, Fusion Protein, Erythropoietin,  Vaccines and Others), and by Disease Indication (Age-related Macular Degeneration, Ankylosing Spondylitis, Psoriatic Arthritis, Hepatitis B, Ulcerative Colitis, Cystic Fibrosis, Rheumatoid Arthritis, Anemia, Diabetes, and Others (Cardiac Diseases and Others)), was worth US$ 116.0 billion in 2018 and is expected to grow at a CAGR of 10.2% over the forecast period (2018–2026).

Get Your FREE Sample Copy of the U.S. Non-oncology Biopharmaceuticals Market Report 2021

Increased launch and approval of novel biopharmaceuticals, as well as a solid pipeline of biopharmaceutical products in late-stage clinical trials, are likely to propel the non-oncology biopharmaceuticals market in the United States. For example, Leadiant Biosciences, Inc. got FDA approval for its Revcov (elapegademase-lvlr) injection in the United States in October 2018. Revcovi is a new enzyme replacement therapy (ERT) for pediatric and adult patients with adenosine deaminize severe combination immune deficiency (ADA-SCID). In addition, significant businesses participate in the development and launch of innovative biopharmaceuticals for new indications. In May 2018, Novartis announced that the US Food and Drug Administration had approved Aimovig (erenumab) for the prevention of migraine in adults. The human monoclonal antibody Aimovig was the first to be approved for the treatment of migraines. In September 2018, the FDA approved Emgality (galcanezumab-gnlm) and AJOVY (fremanezumab-vfrm) for the prevention of migraine in adults, respectively, from Eli Lilly and Company and Teva Pharmaceutical Industries Ltd. The launch of novel medications for new indications is likely to support the growth of the non-oncology biopharmaceuticals market in the United States.

Buy Now this Premium Report to Grow your Business: https://www.coherentmarketinsights.com/insight/buy-now/2575

Strategic mergers, collaborations, acquisitions, and partnerships are being pursued by key market participants in order to develop novel biopharmaceuticals and extend their portfolios through strategic acquisitions of any company. Teva Pharmaceutical Industries Ltd. and Celltrion, Inc., for example, formed an exclusive agreement in October 2018 to commercialize two of Celltrion’s mAb biosimilar candidates in the U.S. and Canada. Risankizumab was bought by AbbVie Inc. from Boehringer Ingelheim (BI) in 2016. (BI 655066). Risankizumab is a psoriasis drug that is an anti-IL-23 monoclonal biologic antibody. The medicine is also being tested for other indications such as Crohn’s disease, asthma, and psoriatic arthritis, according to the company. It is currently in the third round of clinical trials. Furthermore, the loss of patents for major drugs like Humira and the launch of low-cost biosimilars is expected to be a major factor reducing the revenue generated by major drugs, which is expected to have a negative impact on the overall size and growth of the non-oncology biopharmaceutical market in the United States over the forecast period. For example, in the recent past, Sandoz Inc., Boehringer Ingelheim GmbH, and Amgen Inc. won FDA approval in the United States for biosimilar copies of AbbVie Inc.’s blockbuster medication, Humira (adalimumab). Most of these businesses, however, have negotiated an agreement with AbbVie Inc. to postpone the launch of a Humira copycat until 2023.

View Press Release For More Information

Key Takeaways:

Due to increased product releases and approvals, as well as a healthy pipeline of innovative non-oncology biopharmaceuticals in the United States, the non-oncology biopharmaceuticals market in the United States is predicted to grow at a CAGR of 10.2 percent from 2018 to 2026.

The United States is the most profitable economy for monoclonal antibodies, as most significant firms such as AbbVie Inc., Roche Holding AG, and Merck & Co. get the majority of their revenue from biological products sold in the United States.

Several key biologics, including Remicade and Humira, have recently lost their patent protection in the United States. In addition, several more high-profit biologics are projected to lose their patents in the near future. The loss of patents in the United States presents a profitable opportunity for other companies to create biosimilars.

Key market participants have attractive prospects to create novel and creative therapeutics for a variety of rare diseases, with a focus on underserved people. Acts like the Orphan Drug Act help companies explore new treatments for uncommon diseases by providing financial incentives.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Drug Class
      • Market Snippet, By Disease Indication
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Recent Product Approval/Launch
    • Merger-Acquisition Scenario
    • Regulatory Scenario
    • Reimbursement Scenario
    • Pest Analysis
    • Market Challenges
    • Top 10 Non-oncology Biologics Brand Share
    • Major Biopharmaceuticals Administration Method
    • Analysis Of Mode Of Administration
    • Epidemiology
    • Pest Analysis
    • Porter’s Five Forces Analysis
  4. U.S. Non-oncology Biopharmaceuticals Market, By Product Type, 2016 – 2026 (US$ Bn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017–2026
      • Segment Trends
    • Biologics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Biosimilars
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
  5. U.S. Non-oncology Biopharmaceuticals Market, By Drug Class, 2016 – 2026 (US$ Bn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017–2026
      • Segment Trends
    • Blood Factors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Botulinum Toxin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Colony-stimulating Factor
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Enzyme Replacement Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Erythropoietin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Fusion Protein
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Human Growth Hormone
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Interferon
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Monoclonal Antibody
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Recombinant Human Insulin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Vaccines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
  6. U.S. Non-oncology Biopharmaceuticals Market, By Disease Indication, 2016 – 2026 (US$ Bn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017–2026
      • Segment Trends
    • Age-related Macular Degeneration
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Anemia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Ankylosing Spondylitis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Crohn’s Disease
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Cystic Fibrosis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Diabetes
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Hemophilia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Hepatitis B
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Multiple Sclerosis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Osteoporosis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Psoriasis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Psoriatic Arthritis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Rheumatoid Arthritis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Ulcerative Colitis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
  7. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

Ask for PDF sample copy of the U.S. Non-oncology Biopharmaceuticals market report @ https://www.coherentmarketinsights.com/insight/request-pdf/2575

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Sign up and submit a press release

Sponsored
C-mo Medical Solutions extends seed investment round to €4.8 million to transform cough monitoring

C-mo Medical Solutions extends seed investment round to €4.8 million to transform cough monitoring

New Clarius Power Fan HD3 Delivers a First for Handheld Ultrasound: Continuous Scanning

New Clarius Power Fan HD3 Delivers a First for Handheld Ultrasound: Continuous Scanning

Fluidx Unveils New Embolic for Neurovascular Use

Fluidx Unveils New Embolic for Neurovascular Use

Annalise.ai and Nuance Communications (a Microsoft Company) Announce Key Partnership to Improve Patient Outcomes with Workflow-Integrated AI

Annalise.ai and Nuance Communications (a Microsoft Company) Announce Key Partnership to Improve Patient Outcomes with Workflow-Integrated AI

PT Genie Unveils New Brand Identity Reflecting Company’s Transformation and Focus on the Global Future of AI and Machine Learning in Digital Healthcare

interviews & reviews
Balance Boards to Stay Active in the Offfice: Interview with Joel Heath, CEO of FluidStance 

Balance Boards to Stay Active in the Offfice: Interview with Joel Heath, CEO of FluidStance 

Exciting Medtech at the Healthcareᐩ Expo Taiwan

Exciting Medtech at the Healthcareᐩ Expo Taiwan

Medgadget Visits Healthcareᐩ Expo Taiwan

Medgadget Visits Healthcareᐩ Expo Taiwan

Diabetes Management Tech for Type II patients: Interview with Jeffrey Brewer, CEO of Bigfoot Biomedical

Diabetes Management Tech for Type II patients: Interview with Jeffrey Brewer, CEO of Bigfoot Biomedical

Monitoring Congestive Heart Failure Through Speech: Interview with Tamir Tal, CEO of Cordio Medical

Monitoring Congestive Heart Failure Through Speech: Interview with Tamir Tal, CEO of Cordio Medical

In-Office Pediatric Ear Tube Procedures: Interview with Preceptis Medical's Greg Mielke

In-Office Pediatric Ear Tube Procedures: Interview with Preceptis Medical's Greg Mielke

Symani Microsurgical Robotic System: Interview with Mark Toland, CEO of Medical Microinstruments

Symani Microsurgical Robotic System: Interview with Mark Toland, CEO of Medical Microinstruments

  • Subscribe
  • Contact us
  • Submit
  • About
  • Back to top
Medgadget

Medical technologies transform the world! Join us and see the progress in real time. At Medgadget, we report the latest technology news, interview leaders in the field, and file dispatches from medical events around the world since 2004.

  • About
  • Editorial policies
  • Contact
  • Terms of Service
  • Privacy
  • Submit press release
  • Advertise
© Medgadget, Inc. All rights reserved. | The Medical Revolution Will Be Blogged.
Please support this website by adding us to your whitelist in your ad blocker. Ads are what helps us bring you premium content! Thank you!
Posting....
  • Facebook
  • Twitter
  • LinkedIn
  • Reddit
  • Email